Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Core Insights - Anixa Biosciences has announced the final results of its Phase 1 clinical trial for a breast cancer vaccine, which will be presented at the 2025 San Antonio Breast Cancer Symposium [1][2][3] - The trial, funded by the U.S. Department of Defense, evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer [2][3] - The results are expected to inform discussions with the FDA and advance plans for Phase 2 development [1][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company’s vaccine technologies target "retired" proteins expressed in certain cancers, including breast and ovarian cancer, developed at Cleveland Clinic and exclusively licensed to Anixa [4] - Anixa's business model involves partnerships with leading research institutions to explore emerging technologies for further development and commercialization [4]